tert-butyl-ammonium fluoride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-butyl-ammonium fluoride
• 英文别名: t-Butylammonium fluoride；tert-butylazanium;fluoride
• 化学式: C₄H₁₁N*FH
• 分子量: 93.1444
• InChiKey: AFXKCBFBGDUFAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.97
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (S)-[1-(4-Bromophenyl)-2,2,2-trifluoro-ethyl]-[1-(tert-butyl-dimethyl-silanyloxymethyl)-4,4,4-trifluoro-butyl]-amine 、 tert-butyl-ammonium fluoride 在 氯化铵 、 乙酸乙酯 、 Brine 、 magnesium sulfate 、 SiO2 、 hexanes 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以to yield (2S)-2-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]amino}-5,5,5-trifluoropentan-1-ol的产率得到(2S)-2-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]amino}-5,5,5-trifluoropentan-1-ol
  参考文献：
  名称：

  Cathepsin cysteine protease inhibitors

  摘要：

  本发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于卡特普西林K、L、S和B的抑制剂。这些化合物对于治疗需要抑制骨吸收的疾病，如骨质疏松症，是有用的。

  公开号：

  US07973037B2
• 作为试剂：
  描述：

  吗啡 、 alkaline earth salt of/the/ methylsulfuric acid 在 palladium on activated charcoal manganese(IV) oxide 、 tert-butyl-ammonium fluoride 、 氢气 、 sodium 作用下， 以 氯仿 为溶剂， 反应 1.83h， 生成 氢吗啡酮
  参考文献：
  名称：

  An improved synthesis of noroxymorphone

  摘要：

  A brief synthesis of noroxymorphone is described which involves the oxidation of 3-O-(t)butyldimethylsilylmorphine by manganese dioxide. The initial product is the corresponding morphinone which is further oxidised to the 14-hydroxymorphinone. After hydrogenation the 7,8-dihydro-14-hydroxymorphinone is acetylated and N-demethylation of the 14-O-acetylated product is achieved using vinyl chloroformate as the reagent. The overall yield from morphine is 40-45%.

  DOI：

  10.1016/s0040-4020(01)80016-8

文献信息

• Pharmaceutically active compounds
  申请人：Astra Pharmaceuticals Limited

  公开号：US05883102A1

  公开（公告）日：1999-03-16

  Compounds of formula (I) wherein: R.sup.1 and R.sup.19 independently represent hydrogen, alkyl C1-6, alkoxy C1-6, alkylthio C1-6, halogen, hydroxyl or amino; R.sup.2 represents H or alkyl; R.sup.3 represents phenyl, a 6-membered heterocyclic aromatic ring containing one or two nitrogen atoms, or a 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O,N, and S, which phenyl or heterocyclic aromatic ring may be optionally substituted by alkyl C1-6, alkoxy C1-6, haologen, hydroxyl, alkylthio C1-6, cyano, trifluoromethyl, nitro, hydroxymethyl, amino, a group --(CH.sub.2).sub.c NHCO.sub.2 R.sup.10, a group --(CH.sub.2).sub.c NR.sup.5 R.sup.6, or a group --CO.sub.2 R.sup.11 ; or R.sup.3 represents hydrogen or alkyl C1-8, which alkyl group may be optionally substituted by amino or a group --NHCO.sub.2 R.sup.10 ; R.sup.4 represents hydrogen or alkyl C1-6; or R.sup.3 and R.sup.4 taken together represent a group (CH.sub.2).sub.a Z(CH.sub.2).sub.b ; c represents an integer 0 to 2; and pharmaceutically acceptable salts thereof, have been found to be useful as a pharmaceuticals. The compounds may especially be used in the treatment of inflammatory disorders.

  公式(I)的化合物，其中：R 1和R 19独立代表氢、烷基C 1-6、烷氧基C 1-6、烷硫基C 1-6、卤素、羟基或氨基；R 2代表H或烷基；R 3代表苯基，含有一个或两个氮原子的六元杂环芳环，或含有1至3个分别选自O、N和S的杂原子的五元杂环芳环，其中苯基或杂环芳环可任选地被烷基C 1-6、烷氧基C 1-6、卤素、羟基、烷硫基C 1-6、氰基、三氟甲基、硝基、羟甲基、氨基、基团--(CH 2) c NHCO 2 R 10，基团--(CH 2) c NR 5 R 6，或基团--CO 2 R 11取代；或R 3代表氢或烷基C 1-8，其中烷基可任选地被氨基或基团--NHCO 2 R 10取代；R 4代表氢或烷基C 1-6；或R 3和R 4共同代表基团(CH 2) a Z(CH 2) b；c代表整数0至2；及其药物可接受的盐，发现用作药物是有用的。这些化合物特别可用于治疗炎症性疾病。
• Heterocyclic beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020028832A1

  公开（公告）日：2002-03-07

  This invention provides compounds of Formula I having the structure 1 U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  这项发明提供了具有结构式I的化合物 1 其中U、V、W、X和Y如前文所定义， 或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。
• Inhibitors of farnesyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US05856326A1

  公开（公告）日：1999-01-05

  The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

  本发明涉及抑制法尼基-蛋白转移酶（FTase）和致癌基因蛋白Ras法尼酰化的化合物。该发明还涉及含有本发明化合物的化疗组合物以及抑制法尼基-蛋白转移酶和致癌基因蛋白Ras法尼酰化的方法。
• Sulphonamido-substituted bridged bicycloalkyl derivatives
  申请人：——

  公开号：US20040029862A1

  公开（公告）日：2004-02-12

  A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.

  揭示了一类化合物，包括磺胺基取代的桥联双环烷基结构。这些化合物是γ-分泌酶的抑制剂，因此在治疗和/或预防阿尔茨海默病方面是有用的。
• Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
  申请人：——

  公开号：US20030166573A1

  公开（公告）日：2003-09-04

  An oxadiazole derivative of formula (I) and a non-toxic salt thereof, 1 wherein R is hydrogen, alkyl, CycA, etc.; AA 1 is a single bond, amino acid residue, etc.; AA 2 is a single bond, amino acid residue, etc.; R 7 and R 8 are hydrogen, alkyl, etc.; R 9 is hydrogen, alkyl, etc.; R 10 is hydrogen, alkyl, etc.). The compound of formula (I) has an inhibitory activity against cysteine protease and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases, diseases induced by apoptosis, diseases induced by disorders of immune responses, autoimmune diseases, diseases induced by decomposition of proteins which compose organism, shock, circulatory system disorders, blood coagulation system disorders, malignant tumors, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitic diseases, nerve degeneration diseases, pulmonary disorders, bone resorption diseases, endocrinesthenia, etc.

  公式（I）的一种噁二唑衍生物及其非毒性盐，其中R为氢、烷基、环烷A等；AA1为单键、氨基酸残基等；AA2为单键、氨基酸残基等；R7和R8为氢、烷基等；R9为氢、烷基等；R10为氢、烷基等。公式（I）的化合物具有对半胱氨酸蛋白酶的抑制活性，因此它可用作预防和/或治疗炎症性疾病、细胞凋亡诱导的疾病、免疫反应紊乱诱导的疾病、自身免疫疾病、由组成生物体的蛋白质分解诱导的疾病、休克、循环系统紊乱、血液凝固系统紊乱、恶性肿瘤、获得性免疫缺陷综合症（AIDS）和AIDS相关综合症（ARC）、寄生虫病、神经退行性疾病、肺部疾病、骨吸收疾病、内分泌虚弱等方面的药物。